Apyx Medical Toekomstige groei
Future criteriumcontroles 1/6
De verwachting is dat Apyx Medical de winst en omzet met respectievelijk 2.3% en 14.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 5.1% per jaar.
Belangrijke informatie
2.3%
Groei van de winst
5.10%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 15.6% |
| Inkomstengroei | 14.6% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 13 Apr 2026 |
Recente toekomstige groei-updates
Recent updates
APYX: GLP-1 Skin Tightening Demand Will Support Future Upside
Analysts have lifted their price targets on Apyx Medical to $6, up from $5, citing a strong quarter; 2026 guidance above prior Street expectations; early traction from the Ayon launch; and potential upside from new product approvals, GLP-1 related skin tightening demand, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $6 price target as reflecting stronger confidence in execution after a quarter where sales were in line and earnings were ahead of prior expectations, which they view as supportive for valuation.APYX: GLP-1 Skin Tightening Trend Will Drive Future Upside
Narrative Update on Apyx Medical The updated analyst price target for Apyx Medical moves to $6, with analysts pointing to a strong quarter, 2026 guidance that is ahead of Street expectations, early traction from the Ayon launch, growing skin tightening demand linked to GLP-1 usage, and expansion opportunities outside the U.S. as key supports for the change. Analyst Commentary Recent Street research on Apyx Medical centers on a higher $6 price target and an upgrade to a more constructive stance, driven by operational updates, new product traction, and exposure to GLP-1 related demand trends.APYX: GLP-1 Procedure Demand And International Expansion Will Drive Future Upside
Narrative Update: Apyx Medical Apyx Medical's updated fair value estimate edges up from $6.00 to $6.40 as analysts point to a higher Street price target of $6.00, recent earnings outperformance, 2026 guidance that sits above prior expectations, and additional growth opportunities tied to new product approvals, GLP-1 related demand, and international expansion. Analyst Commentary Recent Street commentary on Apyx Medical is broadly constructive, with analysts pointing to a combination of product momentum, new procedure use cases, and international expansion as key inputs to their updated valuation work.APYX: Strong Revenue Outlook Will Support Future Single Platform Adoption
Analysts have raised their Apyx Medical price target to $6.00, up from $6.00, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E that together refine their view of the stock's risk and earnings potential. What's in the News Apyx Medical issued preliminary revenue guidance for fourth quarter 2025, with management expecting revenue between $19.0 million and $19.2 million, which the company states represents a 34% year over year increase (Key Developments).APYX: Single Console Platform Will Drive Future Adoption And Margin Expansion
Analysts have modestly adjusted their price target framework for Apyx Medical, reflecting updated assumptions around profit margin and future P/E that contribute to a refined view of fair value at $6.00 per share. What's in the News Apyx Medical issued preliminary revenue guidance for the fourth quarter of 2025, with expected revenue between $19.0m and $19.2m, described by the company as approximately 34% year over year growth (company guidance).APYX: Single Console Platform Will Drive Wider Adoption And Margin Expansion
Narrative Update on Apyx Medical Analysts have raised their price target on Apyx Medical to US$8, reflecting increased confidence that the AYON all in one console, which integrates Renuvion with additional surgical offerings, can attract physicians through its differentiated technology, workflow benefits, and broad patient appeal. Analyst Commentary Recent research updates are framing Apyx Medical as a company where expectations are increasingly tied to execution on the AYON platform and its potential impact on growth, margins, and valuation.Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26%
Feb 03
APYX: Single Console Platform Will Support Future Procedure And Workflow Adoption
Analysts have raised their price target on Apyx Medical to $8, pointing to the AYON system's integrated console design, use of the legacy Renuvion technology, and its appeal to physicians as key supports for the updated view. Analyst Commentary Recent analyst commentary around Apyx Medical has focused on how the AYON system could influence the company’s growth path, execution risks, and valuation framework.Is Apyx Medical Corporation (NASDAQ:APYX) Trading At A 45% Discount?
Jan 13APYX: Single Console Platform Will Drive Future Procedure Adoption Upswing
Analysts have nudged their fair value target for Apyx Medical to $6.00 per share, citing greater confidence in the AYON system's all in one console design and its potential appeal to physicians and a broadening patient base. Analyst Commentary Bullish Takeaways Bullish analysts point to the AYON system's all in one, single console design as a core driver for their higher fair value targets, arguing that a unified platform can support more efficient procedure volumes and revenue per installed unit over time.APYX: New Surgical Console Rollout Will Drive Stronger Demand Inflection
Analysts have modestly raised their price target on Apyx Medical to $8.00, citing increasing confidence that the AYON system can drive faster adoption and enhance the company’s long term growth and profitability profile. Analyst Commentary Analyst feedback on Apyx Medical has been largely constructive, with the AYON system viewed as a key catalyst for accelerating revenue growth and improving the company’s valuation profile.APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection
Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum
Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story
Nov 18Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Nov 07APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities
Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.Even With A 26% Surge, Cautious Investors Are Not Rewarding Apyx Medical Corporation's (NASDAQ:APYX) Performance Completely
Oct 04Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Sep 19A Piece Of The Puzzle Missing From Apyx Medical Corporation's (NASDAQ:APYX) 34% Share Price Climb
Jul 26The Market Doesn't Like What It Sees From Apyx Medical Corporation's (NASDAQ:APYX) Revenues Yet As Shares Tumble 25%
Apr 23
AYON Launch And Restructuring Will Create Lasting Opportunities
The launch of the AYON Body Contouring System may significantly drive revenue growth through market expansion and increased equipment sales.Apyx Medical Corporation's (NASDAQ:APYX) Shares Lagging The Industry But So Is The Business
Mar 05Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Dec 19Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Nov 23Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Sep 14Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 07We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Aug 01Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Jun 19Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Apr 18Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Mar 26Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)
Feb 16Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 76 | -8 | -4 | N/A | 2 |
| 12/31/2027 | 64 | -12 | -9 | -11 | 5 |
| 12/31/2026 | 58 | -14 | -13 | -16 | 5 |
| 12/31/2025 | 53 | -11 | -9 | -8 | N/A |
| 9/30/2025 | 48 | -15 | -9 | -8 | N/A |
| 6/30/2025 | 47 | -17 | -10 | -9 | N/A |
| 3/31/2025 | 47 | -20 | -13 | -12 | N/A |
| 12/31/2024 | 48 | -23 | -19 | -18 | N/A |
| 9/30/2024 | 49 | -28 | -18 | -17 | N/A |
| 6/30/2024 | 49 | -28 | -10 | -9 | N/A |
| 3/31/2024 | 50 | -23 | -10 | -10 | N/A |
| 12/31/2023 | 52 | -19 | -6 | -5 | N/A |
| 9/30/2023 | 50 | -15 | -8 | -8 | N/A |
| 6/30/2023 | 47 | -16 | -17 | -17 | N/A |
| 3/31/2023 | 44 | -21 | -18 | -18 | N/A |
| 12/31/2022 | 45 | -23 | -21 | -20 | N/A |
| 9/30/2022 | 49 | -19 | -17 | -16 | N/A |
| 6/30/2022 | 51 | -18 | -15 | -14 | N/A |
| 3/31/2022 | 52 | -16 | -14 | -13 | N/A |
| 12/31/2021 | 49 | -15 | -11 | -10 | N/A |
| 9/30/2021 | 43 | -15 | -12 | -12 | N/A |
| 6/30/2021 | 38 | -14 | -11 | -11 | N/A |
| 3/31/2021 | 31 | -15 | -11 | -11 | N/A |
| 12/31/2020 | 28 | -12 | -17 | -16 | N/A |
| 9/30/2020 | 25 | -16 | -19 | -18 | N/A |
| 6/30/2020 | 25 | -16 | -21 | -20 | N/A |
| 3/31/2020 | 28 | -16 | -22 | -21 | N/A |
| 12/31/2019 | 28 | -20 | -20 | -18 | N/A |
| 9/30/2019 | 26 | -18 | N/A | -33 | N/A |
| 6/30/2019 | 22 | -15 | N/A | -30 | N/A |
| 3/31/2019 | 19 | -14 | N/A | -25 | N/A |
| 12/31/2018 | 17 | -11 | N/A | -21 | N/A |
| 9/30/2018 | 14 | -10 | N/A | -2 | N/A |
| 6/30/2018 | 13 | -12 | N/A | -1 | N/A |
| 3/31/2018 | 5 | -15 | N/A | -2 | N/A |
| 12/31/2017 | 10 | -14 | N/A | -4 | N/A |
| 9/30/2017 | -12 | -19 | N/A | -5 | N/A |
| 6/30/2017 | -4 | -17 | N/A | -4 | N/A |
| 3/31/2017 | 37 | -4 | N/A | -3 | N/A |
| 12/31/2016 | 9 | -12 | N/A | -3 | N/A |
| 9/30/2016 | 35 | -5 | N/A | -3 | N/A |
| 6/30/2016 | 33 | -5 | N/A | -4 | N/A |
| 3/31/2016 | 31 | -6 | N/A | -6 | N/A |
| 12/31/2015 | 30 | 8 | N/A | -6 | N/A |
| 9/30/2015 | 29 | 4 | N/A | -5 | N/A |
| 6/30/2015 | 28 | 3 | N/A | -3 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat APYX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat APYX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat APYX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van APYX ( 14.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 11.1% per jaar).
Hoge groei-inkomsten: De omzet van APYX ( 14.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van APYX naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/01 08:31 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Apyx Medical Corporation wordt gevolgd door 7 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| David Turkaly | Citizens JMP Securities, LLC |